Correlation between clinicopathological characteristics and the clinical prognosis of patients with gastroenteropancreatic neuroendocrine tumors

被引:1
|
作者
Fan, Dongwei [1 ]
Li, Xuanhe [2 ]
Yu, Yousheng [1 ]
Wang, Xingliang [1 ]
Fang, Jun [1 ]
Huang, Cheng [1 ,3 ]
机构
[1] West Anhui Hlth Vocat Coll, Affiliated Hosp, Dept Gen Surg, Luan 237000, Anhui, Peoples R China
[2] Bengbu Med Coll, Affiliated Hosp 1, Dept Surg Oncol, Bengbu 233000, Anhui, Peoples R China
[3] West Anhui Hlth Vocat Coll, Affiliated Hosp, Dept Gen Surg, 73 Mozitan Rd, Luan 237000, Anhui, Peoples R China
关键词
gastroenteropancreatic neuroendocrine tumor; clinical and pathological characteristics; prognostic factors; SERUM CHROMOGRANIN-A; CONSENSUS GUIDELINES; DIAGNOSIS; MANAGEMENT; CLASSIFICATION; RATIONALE; NEOPLASMS; FEATURES; TRACT;
D O I
10.3892/mco.2023.2681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are one of the most common types of NETs, accounting for 65-75% of all NETs. However, epidemiological characteristics of patients with GEP-NETs in China are still lacking. The present retrospective study aimed to investigate the local epidemiology of GEP-NETs and assess the prognostic factors in China. The data of 267 patients with GEP-NETs who were admitted to the First Affiliated Hospital of Bengbu Medical College (Bengbu, China) and the Affiliated Hospital of West Anhui Health Vocational College (Lu'an, China) were retrospectively reviewed. The clinical and pathological characteristics of the patients, as well as follow-up information, were collected, and the 5-year survival rate was calculated. Kaplan-Meier curves and log-rank analysis were used to analyze the prognostic factors. The stomach (100/267; 37.5%) was the most common site of GEP-NETs and the liver (25/39; 64.1%) was the most common metastatic site. A total of 166 (62.2%) and 219 (82.0%) patients had positive results for chromogranin A (CgA) and synaptophysin (Syn), respectively. The percentage of patients with tumor grade G1, G2 and G3 was 33.3, 21.0 and 45.7%, respectively. The 5-year overall survival rate was 79.7%, and the age, tumor site, distant metastasis and tumor grading upon diagnosis were all prognostic factors. In conclusion, the present case series investigated the epidemiology and prognostic factors of GEP-NETs in China. CgA and Syn could be used as diagnostic markers for NETs and the stomach was the most common primary tumor site. Lymph node metastasis, tumor site, distant metastasis and tumor grading were important prognostic factors.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Gastroenteropancreatic Neuroendocrine Tumors: Does Tumor Location Affect Prognosis?
    Ozsoy, Mehmet Sait
    Erol, Cem Ilgin
    Aydemir, Muhammet Ali
    Baysal, Hakan
    Buyuker, Fatih
    Seneldir, Hatice
    Ekinci, Ozgur
    Eren, Tunc
    Alimoglu, Orhan
    ARCHIVES OF IRANIAN MEDICINE, 2025, 28 (01) : 29 - 39
  • [22] Catecholamine production in patients with gastroenteropancreatic neuroendocrine tumors
    Ciofu, A
    Baudin, E
    Chanson, P
    Cailleux, AF
    Comoy, E
    Sabourin, JC
    Ducreux, M
    Schaison, G
    Schlumberger, M
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (05) : 434 - 437
  • [23] Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre
    Shouki Bazarbashi
    Mohamed Aseafan
    Tasnim Elgazzar
    Maha Alkhayat
    Abdulrahman Alghabban
    Marwa I. Abdelgawad
    Bader Alshamsan
    Aisha Alshibany
    Tusneem Elhassan
    Ali Aljubran
    Ahmed Alzahrani
    Hindi Alhindi
    Hussein Raef
    BMC Endocrine Disorders, 23
  • [24] Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre
    Bazarbashi, Shouki
    Aseafan, Mohamed
    Elgazzar, Tasnim
    Alkhayat, Maha
    Alghabban, Abdulrahman
    Abdelgawad, Marwa I. I.
    Alshamsan, Bader
    Alshibany, Aisha
    Elhassan, Tusneem
    Aljubran, Ali
    Alzahrani, Ahmed
    Alhindi, Hindi
    Raef, Hussein
    BMC ENDOCRINE DISORDERS, 2023, 23 (01)
  • [25] THE CLINICAL USE OF INTERFERONS IN THE MANAGEMENT OF NEUROENDOCRINE GASTROENTEROPANCREATIC TUMORS
    OBERG, K
    ERIKSSON, B
    JANSON, ET
    MOLECULAR AND CELL BIOLOGICAL ASPECTS OF GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE, 1994, 733 : 471 - 478
  • [26] Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors
    Lebtahi, R
    Cadiot, G
    Sarda, L
    Daou, D
    Faraggi, M
    Petegnief, Y
    Mignon, M
    LeGuludec, D
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (06) : 853 - 858
  • [27] Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Hasegawa, Sho
    Kobayashi, Noritoshi
    Tokuhisa, Motohiko
    Goto, Ayumu
    Takano, Shoko
    Takada, Yuuki
    Kaneta, Tomohiro
    Mori, Ryutaro
    Matsuyama, Ryusei
    Endo, Itaru
    Yamanaka, Shoji
    Nakajima, Atsushi
    Inoue, Tomio
    Ichikawa, Yasushi
    DIGESTION, 2017, 96 (01) : 13 - 20
  • [28] Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation
    Daichi Hayashi
    Jaroslaw N. Tkacz
    Stephen Hammond
    Brooke C. Devenney-Cakir
    Souhil Zaim
    Nadia Bouzegaou
    Souhila Ounadjela
    Ali Guermazi
    Japanese Journal of Radiology, 2011, 29 : 85 - 91
  • [29] Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation
    Hayashi, Daichi
    Tkacz, Jaroslaw N.
    Hammond, Stephen
    Devenney-Cakir, Brooke C.
    Zaim, Souhil
    Bouzegaou, Nadia
    Ounadjela, Souhila
    Guermazi, Ali
    JAPANESE JOURNAL OF RADIOLOGY, 2011, 29 (02): : 85 - 91
  • [30] The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors
    Lawrence, Ben
    Gustafsson, Bjorn I.
    Kidd, Mark
    Pavel, Marianne
    Svejda, Bernhard
    Modlin, Irvin M.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (01) : 111 - +